Navigation Links
Mayo Clinic researchers discover and manipulate molecular interplay that moves cancer cells
Date:3/29/2009

JACKSONVILLE, Fla. Based on research that reveals new insight into mechanisms that allow invasive tumor cells to move, researchers at the Mayo Clinic campus in Florida have a new understanding about how to stop cancer from spreading. A cancer that spreads elsewhere in the body, known as metastasis, is the process that most often leads to death from the disease.

In the March 29 online issue of Nature Cell Biology, researchers say that a molecule known as protein kinase D1 (PKD1) is key to the ability of a tumor cell to "remodel" its structure, enabling it to migrate and invade. The researchers found that if PKD1 is active, tumor cells cannot move, a finding they say explains why PKD1 is silenced in some invasive cancers.

During metastasis, invasive cancer cells respond to biological signals to move away from a primary tumor. Multiple research groups at Mayo Clinic in Florida are especially interested in this process. One team, led by cancer biologist Peter Storz, Ph.D., has been investigating a process known as actin remodeling at the leading edge - the most forward point - of these migrating tumor cells.

"The events that reorganize the actin cytoskeleton at the leading edge are complex a multitude of molecules act in concert," Dr. Storz says. "But it appears that PKD1 must be turned off if cancer cells are to migrate."

Actin filaments help make up the cytoskeleton of cells. For cancer cells to move, the actin-based cell structure has to be continually reorganized, Dr. Storz says, and to do this, new actin filaments need to be generated to shift the cell forward.

Dr. Storz' group discovered that PKD1 was critical to this process. The researchers found that PKD1 inhibits another protein known as slingshot, which regulates the severing of existing actin structures so that new actin filaments can be synthesized, an event that is essential for cell movement.

The researchers used methods to deplete tumor cells of PKD1 and found that their motility increased. They then expressed activated PKD1 in tumor cells and found that movement was blocked. PKD1 is therefore a negative regulator of directed cell migration, and if PKD1 is not expressed in tumor cells, slingshot will become active and will contribute to the reorganization of actin, and a tumor cell will move, according to researchers.

"This makes sense, because other investigators have found that PKD1 is down-regulated, or turned off, in invasive forms of gastric, prostate, and breast cancer," says Dr. Storz.

So far, investigators have identified a number of players along the pathways that regulate cancer cell movement, from the molecule (RhoaA) that activates PKD1, to the well-known protein (cofilin) that disassembles actin filaments and which is regulated by slingshot. When PKD1 is activated, cofilin does not function and so the cell cannot move.

"Now that we have identified PKD1 as key regulator in processes regulating actin-based directed tumor cell movement, we can begin to think about designing treatments to stop invasive cancer cells from metastasizing," says Dr. Storz. "The basic mechanisms we have uncovered are key to developing those strategies."


'/>"/>

Contact: Paul Scotti
scotti.paul@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related biology news :

1. UC Davis bench-to-bedside research: Promising treatment in clinical trials
2. Alzheimers disease therapeutic prevents long-term damage from TBI in pre-clinical studies
3. Researchers win award for best clinical paper in orthopedic physical therapy
4. ABC publishes monograph on scientific and clinical research of Sinupret
5. Mayo Clinic researchers suspect a novel gene is causing restless legs syndrome in a large family
6. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
7. 3 new informatics pilot projects to aid clinical and translational scientists nationwide
8. Genome Medicine: Bridging the gap between research and clinical practice
9. Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29
10. Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases
11. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... May 23, 2017 , ... Bacterial biofilms, surface adherent communities of ... diverse pathologies ranging from food poisoning and catheter infections to gum disease and the ... tens of billions of dollars per year, there is currently a paucity of means ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... it is exhibiting in booth B2 at the Association for Pathology Informatics ... , In addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, ...
(Date:5/18/2017)... ... 18, 2017 , ... Dr. Ralph Mobbs of the Neuro ... Wales Private Hospital. The procedure was performed on a 46-year-old male patient suffering ... prior to undergoing surgery. , The AxioMed viscoelastic disc is a next-generation disc ...
(Date:5/18/2017)... ... 17, 2017 , ... Cognition Corporation ( http://www.cognition.us ... released version 9.0 of the Cognition Cockpit platform. , “Our whole team has ... Cronin, CEO of Cognition. “We’re thrilled to finally be able to release it ...
Breaking Biology Technology: